Diagnostic opportunities of magnetic resonant imagingmri of heart in differential diagnosis of phenotypical forms of hypertrophic cardiomyopathy

Introduction. Phenotype variants of left ventricular (LV) remodeling in patients with hypertrophic cardiomyopathy (HCM) are often associated with abnormalities of the mitral valve (MV), myocardiumstructure, contributing to the development of medium and/or subaortic obstruction. Itcauses the detail visualization of morphological obstruction substrates, tissue characteristics.

Aim. To evaluate the possibilities of magnetic resonance imaging (MRI) in the diagnosis of various forms of HCM and combined abnormalities.
Materials and methods. 75 patients with suspected HCM were examined. For verification, all patients underwentMRI using protocol: short-pulse T1w-TSE/ T2w-TSE (STIR), gradient echo in cine (CINE), T1-weighted post-contrast images (Inversion Recovery IR-MDE). Results. Patients classified into 4 types according to the anatomical principle (Wiggle E.D. et al., 1985). In addition to the most frequent forms affecting the interventricular septum (IVS) — 64 patients, unusual forms covering the apical zones and papillary muscles — 11 patients. The majority of patients were diagnosed with abnormalities of MV, divided into abnormalities of the number and position of papillary muscles, as well as the ratio of chords and muscles. Myocardial crypts were diagnosed in 12 patients, some combined with areas of non-compact myocardium. Post-contrast visualization using the delayed contrast technique allowed differentiating HCM with accumulation diseases, excluding cavity thrombosis, and evaluating the severity of myocardial fibrosis.
Conclusions. MRI allows to estimate in details anatomic picture of LV remodeling, to diagnose features of the mitral valve, tissue characteristics that allows to stratify risk of sudden death, classify the HCM phenotype form and to determine the volume of surgical intervention.

1. Elliott P., Anastasakis A., Borger M., Borggrefe M.F., Cecchi F., Charron P. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology // Eur. Heart J. 2014. Vol. 35. Р 2733-2779. doi: 10.1093/eurheartj/ehu284.

2. Maron B.J., Maron M.S. Hypertrophic cardiomyopathy // Lancet. 2013. Vol. 381. Р. 242-255. doi: 10.1016/S0140-6736(12)60397-3.

3. Cardim N. (Chair), Galderisi M. (Co-chair), Edvardsen T. et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association // Eur. Heart J. Cardiovascular Imaging. 2015. Vol. 16. Р. 280. doi: 10.1093/ehjci/jeu291.

4. Von Knobelsdorff-Brenkenhoff F., Schulz-Menger J. Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology // J. Cardiovasc. Magn. Reson. 2016. Vol. 18. Р. 6. Published 2016. Jan 22. doi: 10.1186/s12968-016-0225-6.

5. Hoey E.T., Elassaly M., Ganeshan A., Watkin R.W., Simpson H. The role of magnetic resonance imaging in hypertrophic cardiomyopathy // Quant Imaging Med. Surg. 2014 Vol. 4 (5). Р. 397-406. doi: 10.3978/j.issn.2223-4292.2014.09.04.

6. Chan R.H., Maron B.J., Olivotto I., Pencina M.J., Assenza G.E., Haas T.S., Lesser J.R., Gruner C., Crean A.M., Rakowski H., Udelson J.E., Rowin E.J., Lombardi M., Cecchi F., Tomberli B., Spirito P., Formisano F., Biagini E., Rapezzi C., Cecco C.N., Autore C., Cook E.F., Hong S.N., Gibson C.M., Manning W.J., Appelbaum E.A., Maron M. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy // Circulation. 2014. Vol. 130, No. 6. Р 484-495. doi: 10.116l/CIRCULATIONAHA.113.007094.

7. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death // Eur. Heart J. 2015. Vol. 36. Р. 2793-2867. doi: 10.1093/eurheartj/ehv316.

8. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Russian Journal of Cardiology, 2015, No. 5, рр. 7-57 (In Russ.). doi.org/10.15829/1560-4071-2015-5-7-57.

9. American Society of Echocardiography Clinical Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy // J. Am. Soc. Echocardiogr. 2011. Vol. 24. Р. 473-98. doi: 10.1016/j.echo.2011.03.006.

10. Maron M.S., Rowin E.J., Lin D., Appelbaum E., Chan R.H., Gibson C.M., Lesser J.R., Lindberg J., Haas T.S., Udelson J.E., Manning W.J., Maron B.J. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy // Circ. Cardiovasc Imaging. 2012. Vol. 5. Р. 441-447. doi: 10.1161/CIRCIMAGING.112.972760.

11. Deva D.P., Williams L.K., Care M., Siminovitch K.A., Moshonov H., Wintersperger B.J., Rakowski H., Crean A.M. Deep basal inferoseptal crypts occur more commonly in patients with hypertrophic cardiomyopathy due to disease-causing myofilament mutations // Radiology. 2013. Vol. 269. Р. 6876. doi: 10.1148/radiol.13122344.

12. Moon J.C., McKenna W.J. Myocardial crypts: a prephenotypic marker of hypertrophic cardiomyopathy? // Circ. Cardiovasc. Imaging. 2012. Vol. 5. Р. 431-432. doi: 10.1161/CIRCIMAGING.112.975888.

13. Briasoulis A., Mallikethi-Reddy S., Palla M. et al Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analy-sis // Heart. 2015. Vol. 101. Р. 1406-1411. doi: 10.1136/heartjnl-2015-307682.

14. Freitas P., Ferreira A.M., Arteaga-Fernandez E. et al. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death // J. Cardiovasc. Magn. Reson. 2019. Vol. 21. Р. 50. doi: 10.1186/s12968-019-0561-4.